Literature DB >> 15732002

The hepatitis C virus alternate reading frame (ARF) and its family of novel products: the alternate reading frame protein/F-protein, the double-frameshift protein, and others.

Andrea D Branch1, Decherd D Stump, Julio A Gutierrez, Francis Eng, José L Walewski.   

Abstract

The hepatitis C virus (HCV) has an alternate reading frame (ARF) that overlaps the core protein gene. The overlapping reading frame distinguishes HCV from all of its known viral relatives, with the possible exception of GB virus B (GBV-B). The ARF is expressed during natural HCV infections and stimulates specific immune responses. Like several essential genes in other viruses (e.g., the human immunodeficiency virus polymerase) the ARF lacks an in-frame AUG start codon, suggesting that its expression involves unusual translation-level events. In vitro studies indicate that ribosomal frameshifting may be one of several processes that can lead to translation of the ARF. Frameshifting yields chimeric proteins that have segments encoded in the core gene covalently attached to amino acids encoded in the ARF. A consistent nomenclature for the ARF's protein products has yet to be established. We propose that all proteins that contain amino acids encoded in the + 1 ARF be called alternate reading frame proteins (ARFPs) and that specific ARFPs, such as the ARFP/F-protein, the double-frameshift protein, and the short form of core + 1, be designated as follows: ARFP/F (ARFP/F-protein), ARFP/DF (double-frameshift), and ARFP/S (short form of core + 1). The roles of ARFPs in the HCV life cycle are not yet known. There is a significant possibility that ARFPs may be responsible for some of the effects attributed to the core protein, given that most studies seeking to define the function of the core protein have employed materials likely to contain a combination of the core protein and ARFPs. The observed effects of the core protein include the induction of liver cancer, transformation of cells, and alterations of immune responses. This article reviews the discovery of ARF, describes the RNA structural elements involved in core/ARF gene expression, discusses possible functions of ARFPs, and considers the potential usefulness of ARFPs in vaccines. The HCV ARF is the focus of a new and rapidly expanding area of research, and the results of many ongoing studies are currently available in abstract form only. The preliminary nature of investigations that have not yet been reviewed by peers is noted in the text.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15732002     DOI: 10.1055/s-2005-864786

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  38 in total

Review 1.  Studying hepatitis C virus: making the best of a bad virus.

Authors:  Timothy L Tellinghuisen; Matthew J Evans; Thomas von Hahn; Shihyun You; Charles M Rice
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

2.  Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle.

Authors:  Ayaz M Majid; Heather Ezelle; Sangeeta Shah; Glen N Barber
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

3.  Characterization of a canine homolog of hepatitis C virus.

Authors:  Amit Kapoor; Peter Simmonds; Gisa Gerold; Natasha Qaisar; Komal Jain; Jose A Henriquez; Cadhla Firth; David L Hirschberg; Charles M Rice; Shelly Shields; W Ian Lipkin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-24       Impact factor: 11.205

Review 4.  Ribosomal frameshifting and transcriptional slippage: From genetic steganography and cryptography to adventitious use.

Authors:  John F Atkins; Gary Loughran; Pramod R Bhatt; Andrew E Firth; Pavel V Baranov
Journal:  Nucleic Acids Res       Date:  2016-07-19       Impact factor: 16.971

5.  A long-range RNA-RNA interaction between the 5' and 3' ends of the HCV genome.

Authors:  Cristina Romero-López; Alfredo Berzal-Herranz
Journal:  RNA       Date:  2009-07-15       Impact factor: 4.942

6.  Bats are a major natural reservoir for hepaciviruses and pegiviruses.

Authors:  Phenix-Lan Quan; Cadhla Firth; Juliette M Conte; Simon H Williams; Carlos M Zambrana-Torrelio; Simon J Anthony; James A Ellison; Amy T Gilbert; Ivan V Kuzmin; Michael Niezgoda; Modupe O V Osinubi; Sergio Recuenco; Wanda Markotter; Robert F Breiman; Lems Kalemba; Jean Malekani; Kim A Lindblade; Melinda K Rostal; Rafael Ojeda-Flores; Gerardo Suzan; Lora B Davis; Dianna M Blau; Albert B Ogunkoya; Danilo A Alvarez Castillo; David Moran; Sali Ngam; Dudu Akaibe; Bernard Agwanda; Thomas Briese; Jonathan H Epstein; Peter Daszak; Charles E Rupprecht; Edward C Holmes; W Ian Lipkin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-22       Impact factor: 11.205

7.  Characterization of the specific CD4+ T cell response against the F protein during chronic hepatitis C virus infection.

Authors:  De-Yong Gao; Gen-Di Jin; Bi-Lian Yao; Dong-Hua Zhang; Lei-Lei Gu; Zhi-Meng Lu; Qiming Gong; Yu-Chun Lone; Qiang Deng; Xin-Xin Zhang
Journal:  PLoS One       Date:  2010-12-06       Impact factor: 3.240

Review 8.  Production and pathogenicity of hepatitis C virus core gene products.

Authors:  Hui-Chun Li; Hsin-Chieh Ma; Chee-Hing Yang; Shih-Yen Lo
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

9.  Seroconversion to hepatitis C virus alternate reading frame protein during acute infection.

Authors:  Yoann Morice; Maxime Ratinier; Ahmed Miladi; Stéphane Chevaliez; Georgios Germanidis; Heiner Wedemeyer; Syria Laperche; Jean-Pierre Lavergne; Jean-Michel Pawlotsky
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

10.  Mutations in the hepatitis C virus core gene are associated with advanced liver disease and hepatocellular carcinoma.

Authors:  Sarah L Fishman; Stephanie H Factor; Cinzia Balestrieri; Xiaofeng Fan; Adrian M Dibisceglie; Suresh M Desai; Gary Benson; Andrea D Branch
Journal:  Clin Cancer Res       Date:  2009-04-21       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.